InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the ” Thyroid Eye Disease Market – (By Marketed Treatment (TEPEZZA (Teprotumumab), By Pipeline Treatment (VRDN 001, VB 421, Batoclimab, Linsitnib)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034.”
According to the latest research by InsightAce Analytic, the Thyroid Eye Disease Market is valued at USD 2.26 billion in 2024 , and it is expected to reach USD 4.02 billion by the year 2034 , with a CAGR of 6.0% during the forecast period of 2025-2034.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2893
Thyroid Eye Disease (TED), also known as Graves’ orbitopathy or Graves’ ophthalmopathy, is an autoimmune disorder characterized by inflammation and swelling of the tissues surrounding the eyes. The global market for TED therapeutics is anticipated to demonstrate steady growth over the forecast period, driven primarily by the increasing prevalence of the condition.
Market expansion is supported by advancements in autoimmune disease treatment protocols, enhancements in healthcare infrastructure, and strong patient adherence to prescribed therapies. Rising disposable incomes, coupled with intensified research and development initiatives, are expected to create significant growth opportunities for market participants.
Further, substantial investments by leading industry stakeholders, along with continuous innovation in therapeutic product development, are likely to strengthen the competitive landscape. Government initiatives promoting the use of artificial tears and lubricating eye drops for the management of ocular dryness are also expected to positively influence overall market growth.
List of Prominent Players in the Thyroid Eye Disease Market:
- Horizon Therapeutics
- Viridian Therapeutics
- Pierre Fabre/ACELYRIN
- HanAll Biopharma/Harbour BioMed/Immunovant
- Sling Therapeutics
- Other Market Players
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04
Market Dynamics
Drivers:
The rising prevalence of thyroid eye disease (TED) serves as a primary driver for the global TED therapeutics market. Increased patient adherence to prescribed treatment regimens, combined with ongoing advancements in autoimmune disorder therapies, is expected to substantially support market expansion.
In addition, growing research and development investments by pharmaceutical and biotechnology companies are projected to enhance the market outlook by enabling the development and introduction of more effective therapeutic options.
Challenges:
Despite favorable growth prospects, the market faces several constraints. The absence of a definitive cure for TED, along with limited disease awareness in developing regions, continues to pose significant challenges.
Furthermore, the high cost of treatment may restrict accessibility for certain patient segments, limiting overall market penetration. The COVID-19 pandemic has exacerbated these issues by disrupting global supply chains, delaying production schedules, and constraining the distribution of therapeutic products, resulting in considerable financial impacts for manufacturers, suppliers, and distributors.
Regional Trends:
North America is expected to maintain a dominant position in the TED therapeutics market, capturing a substantial share of global revenue and exhibiting a strong compound annual growth rate (CAGR) over the forecast period. This leadership is attributed to a high prevalence of thyroid-related disorders, continuous innovation in treatment modalities, and active research and development initiatives by leading industry participants.
Europe also represents a key market, supported by advanced healthcare infrastructure and increasing adoption of novel therapeutic solutions. Additionally, the presence of established market players and rising strategic collaborations aimed at geographic expansion are likely to further drive growth across both regions.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2893
Recent Developments:
- In March 2024, ACELYRIN, INC. announced positive proof-of-concept results from a Phase ½ trial of lonigutamab in thyroid eye condition that is now underway. Lonigutamab is a subcutaneous (SC) humanized IgG1 monoclonal antibody that aims the insulin-like growth factor-1 receptor (IGF-1R), a known mechanism of action for thyroid eye disease treatment.
Segmentation of Thyroid Eye Disease Market-
By Marketed Treatment-
- TEPEZZA (Teprotumumab)
By Pipeline Treatment-
- VRDN 001
- VB 421
- Batoclimab
- Linsitnib
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
